Stay updated on Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Sign up to get notified when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.

Latest updates to the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check47 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check69 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.4%
- Check98 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Dose of Insulin Receptor MoAb-IDS in Hunter Syndrome Clinical Trial page.